Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized observer-blind study of VNS varicella vaccine potencies versus Varivax in young children
2022-001910-21Phase 2Completed
- Sponsor
- GSK
- Start
- Oct 2022
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, Live Biotherapeutic Products → Microbiome Therapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of varicella virus vaccine live in chickenpox (4 arms), sponsored by GSK. Primary endpoint: Anti-gE antibody concentration at Day 43. Started Oct 2022; status: completed.
02
Drugs
varicella virus vaccine live
03
Conditions
chickenpox
Beyond the preview
Go deeper on 2022-001910-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001910-21.